Anaplastic thyroid carcinoma: pathogenesis and emerging therapies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic thyroid carcinoma (ATC) accounts for 1.3–9.8% of all thyroid cancers.
• Molecular dysregulation, including gene mutations and altered oncogene/tumor suppressor activity, drives ATC's aggressive nature.
• Preclinical research has identified molecular targets affecting critical cellular processes in ATC.

Purpose of the Study:

• To review the molecular underpinnings of anaplastic thyroid carcinoma.
• To summarize clinical outcomes and survival factors for ATC patients.
• To highlight the need for improved therapeutic strategies.

Main Methods:

• Review of existing literature on ATC molecular biology and clinical studies.
• Analysis of patient data from clinical studies (n=1771) including survival variables.
• Evaluation of treatment efficacy, particularly radiotherapy and emerging systemic therapies.

Main Results:

• Median survival for ATC patients is 5 months, with a 1-year survival rate of 20%.
• Factors influencing survival include age, tumor size, surgery extent, radiotherapy dose, metastasis absence, and co-existing differentiated thyroid cancer.
• Aggressive radiotherapy reduces locoregional recurrence but has not improved overall survival in over 50 years.

Conclusions:

• Despite insights into molecular mechanisms, ATC remains a highly lethal cancer.
• Current treatment strategies, including radiotherapy, have limited impact on overall survival.
• Development of novel and effective systemic combination therapies is urgently needed to improve patient outcomes for anaplastic thyroid carcinoma.